[go: up one dir, main page]

CY1107331T1 - Στερεες τυποποιησεις κετιριζινης ταχειας διαλυσης - Google Patents

Στερεες τυποποιησεις κετιριζινης ταχειας διαλυσης

Info

Publication number
CY1107331T1
CY1107331T1 CY20021100045T CY021100045T CY1107331T1 CY 1107331 T1 CY1107331 T1 CY 1107331T1 CY 20021100045 T CY20021100045 T CY 20021100045T CY 021100045 T CY021100045 T CY 021100045T CY 1107331 T1 CY1107331 T1 CY 1107331T1
Authority
CY
Cyprus
Prior art keywords
solid steel
solution standard
steel solution
standard standards
effervescent
Prior art date
Application number
CY20021100045T
Other languages
English (en)
Inventor
Wolfram Tritthart
Mario Andre Piskernig
Original Assignee
Meda Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meda Pharma Gmbh & Co. Kg filed Critical Meda Pharma Gmbh & Co. Kg
Publication of CY1107331T1 publication Critical patent/CY1107331T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η εφεύρεση σχετίζεται με αναβράζουσες συνθέσεις ταχείας διάλυσης για στοματική εφαρμογή, που περιέχουν κετιριζίνη ή τα φαρμακευτικώς συμβατά άλατα αυτής, μία αναβράζουσα βάση που αποτελείται από τουλάχιστον ένα οργανικό, βρώσιμο οξύ και/ή τα άλατα αυτού, ανθρακικά ή όξινα ανθρακικά άλατα αλκαλίων ή αλκαλικών γαιών και προαιρετικά φαρμακευτικώς ανεκτά πρόσθετα.
CY20021100045T 1998-03-31 2002-03-04 Στερεες τυποποιησεις κετιριζινης ταχειας διαλυσης CY1107331T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19814256A DE19814256A1 (de) 1998-03-31 1998-03-31 Feste, schnellzerfallende Cetirizin-Formulierungen
EP99922050A EP1067904B1 (de) 1998-03-31 1999-03-20 Feste, schnellzerfallende cetirizin-formulierungen

Publications (1)

Publication Number Publication Date
CY1107331T1 true CY1107331T1 (el) 2012-12-19

Family

ID=7863014

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20021100045T CY1107331T1 (el) 1998-03-31 2002-03-04 Στερεες τυποποιησεις κετιριζινης ταχειας διαλυσης

Country Status (31)

Country Link
US (1) US6245353B1 (el)
EP (1) EP1067904B1 (el)
JP (1) JP2002509873A (el)
KR (1) KR100653568B1 (el)
CN (1) CN1136838C (el)
AR (1) AR018828A1 (el)
AT (1) ATE209899T1 (el)
AU (1) AU750140B2 (el)
BG (1) BG64741B1 (el)
BR (1) BR9909233A (el)
CA (1) CA2326809C (el)
CY (1) CY1107331T1 (el)
CZ (1) CZ300704B6 (el)
DE (2) DE19814256A1 (el)
DK (1) DK1067904T3 (el)
ES (1) ES2168013T3 (el)
HK (1) HK1036217A1 (el)
HU (1) HU227477B1 (el)
IL (1) IL138606A (el)
NO (1) NO329071B1 (el)
NZ (1) NZ506988A (el)
PL (1) PL191266B1 (el)
PT (1) PT1067904E (el)
RU (1) RU2216318C2 (el)
SI (1) SI1067904T1 (el)
SK (1) SK284476B6 (el)
TR (1) TR200002809T2 (el)
TW (1) TWI233808B (el)
UA (1) UA57615C2 (el)
WO (1) WO1999049843A1 (el)
ZA (1) ZA200005134B (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7105501A (en) 2000-07-17 2002-01-30 Yamanouchi Pharma Co Ltd Pharmaceutical composition improved in peroral absorbability
MXPA04006775A (es) 2002-01-15 2004-11-10 Ucb Farchim Sa Formulaciones.
CA2481025A1 (en) * 2002-04-04 2003-10-16 Tanya Havlir Palatable chewable tablet
JP2008500288A (ja) * 2004-05-28 2008-01-10 イメイジノット ピーティーワイ エルティーディー 経口治療用化合物の供給系
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
BRPI0517891A (pt) 2004-11-24 2008-10-21 Medpointe Healthcare Inc composições compreendendo azelastina e métodos de uso das mesmas
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20060198885A1 (en) * 2005-02-22 2006-09-07 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical composition
JP2009517346A (ja) 2005-11-28 2009-04-30 イメイジノット ピーティーワイ エルティーディー 治療用化合物の経口送達系
BRPI0918906A2 (pt) * 2008-09-05 2015-12-01 Mcneil Ppc Inc método para a produção de comprimidos de cetirizina
CA2755543A1 (en) * 2009-03-13 2010-09-16 Nucitec S.A. De C.V. Compositions and methods for treatment and prevention of cardiovascular disease
WO2011146032A2 (en) * 2010-05-18 2011-11-24 Mahmut Bilgic Effervescent formulations
CN104363897A (zh) 2012-06-12 2015-02-18 宝洁公司 泡腾剂型
US20140371174A1 (en) 2013-06-12 2014-12-18 The Procter & Gamble Company Effervescent Dosage Form
JP5945191B2 (ja) * 2012-08-09 2016-07-05 株式会社ファンケル 口腔内速崩錠
JP6092672B2 (ja) * 2013-03-21 2017-03-08 株式会社ファンケル 口腔内速崩壊性錠剤
KR101591319B1 (ko) * 2013-12-03 2016-02-18 에프엔바이오 주식회사 홍삼 발포정의 제조방법
TW201605447A (zh) * 2014-06-20 2016-02-16 美林塔治療學有限公司 處理感染的方法
TWI732337B (zh) * 2014-06-20 2021-07-01 美商梅琳塔有限責任公司 醫藥組成物及其用途
EP3061501A1 (en) 2015-02-27 2016-08-31 Rottapharm Ltd. Composition for the treatment of acne
EP3117825A1 (en) 2015-07-16 2017-01-18 Rottapharm S.p.A. Oral formulation comprising berberine and morus alba extract
CN106109422A (zh) * 2016-07-28 2016-11-16 北京万全德众医药生物技术有限公司 盐酸左西替利嗪泡腾颗粒及其制备方法
US10624921B2 (en) 2016-11-15 2020-04-21 Berkeley Nox Limited Dietary supplements
JP2018108950A (ja) * 2016-12-28 2018-07-12 沢井製薬株式会社 レボセチリジン塩酸塩含有口腔内崩壊錠
WO2019099003A2 (en) * 2017-11-15 2019-05-23 Berkeley Nox Limited Novel dietary supplements
EP3799864B1 (en) 2019-10-02 2023-03-01 Intas Pharmaceuticals Limited Essentially sodium-free effervescent solid pharmaceutical compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75816C (fi) * 1981-02-06 1988-08-08 Ucb Sa Foerfarande foer framstaellning av terapeutiskt aktiv 2-/4-(difenylmetyl)-1-piperazinyl/-aettiksyror eller dess amid.
US4678661A (en) * 1983-09-28 1987-07-07 Gerhard Gergely Effervescent composition and method of making same
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
ES2067957T3 (es) * 1990-08-07 1995-04-01 Pfizer Uso de membranas polimerizadas interfacialmente en dispositivos de liberacion.
RU2145219C1 (ru) * 1991-05-13 2000-02-10 Дзе Бутс Компани ПЛС Фармацевтическая композиция, содержащая s(-)-2-(4-изобутилфенил)пропионат натрия, способ получения натриевой соли энантиомера 2-(4-изобутилфенил)пропионовой кислоты, s(-)-2-(4-изобутилфенил)пропионат натрия дигидрат
MX9300110A (es) * 1992-01-13 1994-07-29 Gerhard Gergely Preparacion farmaceutica en la forma de una tableta de efervescencia o de desintegracion o de un granulado de tipo instanteneo y procedimiento para su preparacion.
WO1994008551A2 (en) * 1992-10-09 1994-04-28 The Procter & Gamble Company Pharmaceutical compositions and methods for treating cold symptoms
GB9224021D0 (en) * 1992-11-16 1993-01-06 Boots Co Plc Effervescent compositions
FR2698788B1 (fr) * 1992-12-09 1995-03-03 Union Pharma Scient Appl Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
EP0624364B1 (de) * 1993-04-15 1996-07-24 Gerhard Dr. Gergely Brausesystem mit einem alkali- und/oder metallempfindlichen, pharmazeutischen Wirkstoff, und Verfahren zur Herstellung
WO1994025009A1 (en) * 1993-04-30 1994-11-10 The Procter & Gamble Company Coated pharmaceutical compositions
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions

Also Published As

Publication number Publication date
DK1067904T3 (da) 2002-04-02
HUP0102676A2 (hu) 2001-11-28
TWI233808B (en) 2005-06-11
ATE209899T1 (de) 2001-12-15
CA2326809C (en) 2008-11-18
ZA200005134B (en) 2000-12-21
BR9909233A (pt) 2000-11-28
SI1067904T1 (en) 2002-04-30
CN1136838C (zh) 2004-02-04
KR100653568B1 (ko) 2006-12-05
DE19814256A1 (de) 1999-10-07
HU227477B1 (en) 2011-07-28
CN1295464A (zh) 2001-05-16
CZ20003481A3 (en) 2001-05-16
NO329071B1 (no) 2010-08-16
BG64741B1 (bg) 2006-02-28
DE59900501D1 (de) 2002-01-17
KR20010034718A (ko) 2001-04-25
EP1067904B1 (de) 2001-12-05
HUP0102676A3 (en) 2002-12-28
UA57615C2 (uk) 2003-06-16
WO1999049843A1 (de) 1999-10-07
NO20004722L (no) 2000-09-21
PT1067904E (pt) 2002-05-31
NO20004722D0 (no) 2000-09-21
AU750140B2 (en) 2002-07-11
SK284476B6 (sk) 2005-04-01
CA2326809A1 (en) 1999-10-07
SK14312000A3 (sk) 2001-07-10
CZ300704B6 (cs) 2009-07-22
IL138606A0 (en) 2001-10-31
NZ506988A (en) 2002-05-31
ES2168013T3 (es) 2002-05-16
JP2002509873A (ja) 2002-04-02
PL191266B1 (pl) 2006-04-28
PL343199A1 (en) 2001-07-30
AR018828A1 (es) 2001-12-12
IL138606A (en) 2005-07-25
TR200002809T2 (tr) 2000-12-21
EP1067904A1 (de) 2001-01-17
RU2216318C2 (ru) 2003-11-20
US6245353B1 (en) 2001-06-12
HK1036217A1 (en) 2001-12-28
AU3925399A (en) 1999-10-18
BG104843A (en) 2001-07-31

Similar Documents

Publication Publication Date Title
CY1107331T1 (el) Στερεες τυποποιησεις κετιριζινης ταχειας διαλυσης
TR199902587T2 (xx) Fumarik asid t�revlerinin kullan�lmas�.
CY1105043T1 (el) Υδατοδιαλυτa προφaρμακα παρεμποδισμeνων φαινολων
DE60004060D1 (de) Eletrolytische synthese von peressigsäure
ES2190976T3 (es) Composiciones de n-clorosulfamato que tienen eficacia antimicrobiana mejorada.
NO20024891D0 (no) Farmasöytiske sammensetninger
HRP20000494B1 (en) Pharmaceutically active morpholinol
CY1107992T1 (el) Συνθεσεις πολυαμιδο-αμικου οξεος υδατικης βασεως
MXPA03007650A (es) Solucion de ester glicolico de acido softalico.
BR0307158A (pt) Goma de mascar recheada contendo cálcio
AP9901534A0 (en) Pharmaceutical formulations.
BRPI0017067B8 (pt) inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto
BR9801335A (pt) Composições farmacêuticas sob forma de comprimidos efervescentes contendo um princípio ativo instável na presença de água
ES2184408T3 (es) Sistema transdermico que contiene un antioxidante.
ZA200109236B (en) Pharmaceutical compositions of erythropoietin.
PL351688A1 (en) Carboxyl functional additive for condensing polyamides
CY1116044T1 (el) Μεθοδος για την παρασκευη δισκιων που περιεχουν s-αδενοσυλομεθειονινη
HK1056868A1 (en) Novel dicarboxylic acid derivatives.
ES2163461T3 (es) Procedimiento para la obtencion de comprimidos efervescentes.
CY1106633T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν χαλκο, σαλικυλικο οξυ και βιταμινη c
AR021934A1 (es) Composicion de administracion oral con liberacion controlada de al menos un analgesico
NZ500288A (en) Gastric-retained pharmaceutical composition comprising benzamide as the active principle and a carbon dioxide generating system
MY119880A (en) Prucalopride oral solution
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
MXPA02007903A (es) Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.